BioCentury
ARTICLE | Company News

Acambis discontinuing MVA3000

March 16, 2007 1:21 AM UTC

Acambis (LSE:ACM) said that this year it will wind down activities related to its MVA3000 smallpox vaccine. In November, ACM received notification from the U.S. Department of Health and Human Services that the vaccine was no longer being considered as part of the Modified Vaccinia Ankara (MVA) smallpox vaccine tender process (See BioCentury Extra, Tuesday, Nov. 14, 2006). ACM said it will end the program following the completion of an existing MVA R&D contract with the U.S. National Institutes of Health (NIH) that concludes in September. ...